C-RAD proudly announces their research partnership with PSG Hospitals, Coimbatore, India. The collaboration aims to create awareness of the technology, and to include SGRT in course curriculum. PSG Hospitals is a teaching affiliate of PSG Institute of Medical Sciences and Research’s & Research.
The PSG Hospitals in India is located in Peelamedu, Coimbatore, in the Southern Part of India. The prestigious educational hospital was established in 1985 as a part of PSG & Sons’ Charities. Over the years, PSG has received many awards and accreditations for their outstanding achievements in many different fields of medicine. C-RAD is proud to have them as a research partner.
Dr. T. Balaji, Director Oncology remarked, ‘We recognize patients have choice when it comes to cancer care, and when they choose PSG, we want them to know they have access to all the options for care. In the modern era of radiation oncology where precision is crucial, a C-RAD SGRT technology is the precise answer to stereotactic radiation therapy.’
“We are particularly proud of the partnership with PSG and their modern mindset to SGRT. They feel as strongly as we do that SGRT is the future, and that we need to collaborate broadly to ensure we create awareness across India of the importance of SGRT. The research as well as the collaboration in educating new promising talents within radiation therapy and SGRT will ensure just that.” says Debabrata Bhowmick, Sales Director India, and South Asia
The collaborationis set to start in 2023 and will include several research papers on SGRT from an Indian perspective using the C-RAD Catalyst HD+ system at PSG Institute of Oncology, India. PSG will also be one of the first academic institutions in the world to adopt SGRT into their curriculum for Medical Physicists and Radiotherapy Technologist course, commencing 2023.
“Training & Education as well as research are two important pillars of our strategy for the Indian market. Our strategy has proven to be successful, and I am confident that we can capitalize on our position moving forward. To establish our technology in the market, it is important to team up with leading educational hospitals, such as PSG.” says Tim Thurn, CEO and President of C-RAD AB “The market has a huge demand for advanced cancer care equipment and the commitment from private as well as governmental healthcare provider to invest in radiation therapy to enhance care for patients in need. I am certain that surface tracking will become standard of care in advanced radiation therapy in India.”
C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient’s motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.
C-RAD. Inspiring excellence in cancer treatment.
C-RAD AB is listed on NASDAQ Stockholm.
For more information on C-RAD, please visit https://www.c-rad.com
For further information:
Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email email@example.com